Amgen and Micromet announce early termination of HSR waiting period for Amgen’s acquisition of Micromet
15 February 2012 | By Amgen
Amgen and Micromet entered into a Merger Agreement...
List view / Grid view
15 February 2012 | By Amgen
Amgen and Micromet entered into a Merger Agreement...
15 February 2012 | By Merck
New Brazilian joint venture to combine local and global commercial expertise...
14 February 2012 | By Amgen
"Mike brings broad experience and immense expertise to his new role..."
14 February 2012 | By Biogen Idec
Biogen Idec and Stromedix, Inc. announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc...
13 February 2012 | By Abbott
Accurate and precise lab-to-lab monitoring is essential for long-term transplant success...
13 February 2012 | By Merck
ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution...
13 February 2012 | By Gilead Sciences Inc
The U.S. FDA has granted a six-month Priority Review for once-daily Truvada®...
13 February 2012 | By Novartis
Novartis has received a Complete Response letter from the US FDA...
13 February 2012 | By Bristol-Myers Squibb Company
Completion of the tender offer by Bristol-Myers for all of the outstanding shares of common stock of Inhibitex, Inc...
10 February 2012 | By H. Lundbeck A/S
Lundbeck bolsters its European organization with the appointment of João Rocha and Michael Quiqueran-Beaujeu...
9 February 2012 | By I Holland Ltd
I Holland are now the sole distributor of DF* (Drag Finishing) automated polishing machines and consumables in North America...
8 February 2012 | By kdm communications limited
Syrris, is enjoying outstanding success with sales of Asia, its revolutionary range of advanced flow chemistry products.
8 February 2012 | By Merck
Merck announced that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors...
8 February 2012 | By Bristol-Myers Squibb Company
Apotex has made payment to Sanofi & Bristol-Myers Squibb...
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...